10:30–10:55

Abstract 9000^

Efficacy and safety of the anti-PD-1   monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

抗PD-1单抗（MK-3475）治疗411例黑色素瘤患者的疗效和安全性研究结果。

斯  璐(Lu Si)

Abstract LBA9008

Ipilimumab versus placebo after complete   resection of stage III melanoma: Initial efficacy and safety results from the   EORTC 18071 phase III trial.

Ipillimumab与安慰剂辅助治疗III期黑色素瘤术后患者的III期对照研究（EORTC18071）：初步疗效和安全性结果。

Abstract 9003^

Survival, response duration, and activity   by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558,   ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma.

抗PD-1单抗nivolumab（BMS-936558）联合Ipilimumab（IPI）治疗不同BRAF基因突变状态的晚期黑色素瘤患者的生存、疗效持续时间和活化情况的影响。

10:55-11:05

专家评述

Discussion Topic: Adjuvant immunotherapy for resectable melanoma?

讨论主题：可手术黑色素瘤的辅助免疫治疗？

张晓实(Xiao-Shi Zhang)

11:05-11:10

讨论(Q &   A)

郭  军(Jun Guo)

梁  军(Jun Liang)

张晓实(Xiao-Shi Zhang)